{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:12:43Z","timestamp":1790046763893,"version":"4.0.1"},"reference-count":76,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2003,3,1]],"date-time":"2003-03-01T00:00:00Z","timestamp":1046476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2003,3]]},"DOI":"10.1016\/s1521-6926(02)00089-0","type":"journal-article","created":{"date-parts":[[2003,4,4]],"date-time":"2003-04-04T22:33:30Z","timestamp":1049495610000},"page":"101-116","source":"Crossref","is-referenced-by-count":34,"title":["Cladribine in the treatment of hairy-cell leukaemia"],"prefix":"10.1016","volume":"16","author":[{"given":"Grant R","family":"Goodman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Beutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Saven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S1521-6926(02)00089-0_BIB1","doi-asserted-by":"crossref","first-page":"5677","DOI":"10.1073\/pnas.74.12.5677","article-title":"Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: Possible role of nucleoside kinase(s)","volume":"74","author":"Carson","year":"1977","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB2","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1172\/JCI109201","article-title":"Overproduction of adenine deoxynucleosides and deoxynucleotides in adenosine deaminase deficiency with severe combined immunodeficiency disease","volume":"62","author":"Donofrio","year":"1978","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB3","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/0140-6736(92)92826-2","article-title":"Cladribine (2-chlorodeoxyadenosine)","volume":"340","author":"Beutler","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB4","doi-asserted-by":"crossref","first-page":"6865","DOI":"10.1073\/pnas.77.11.6865","article-title":"Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo","volume":"77","author":"Carson","year":"1980","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB5","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7326\/0003-4819-120-9-199405010-00010","article-title":"2-Chlorodeoxyadenosine: a newer purine analogue active in the treatment of indolent lymphoid malignancies","volume":"120","author":"Saven","year":"1994","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB6","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.4049\/jimmunol.121.5.1726","article-title":"Differential sensitivity of human leukemic T cell lines and B cell lines to growth inhibition by deoxyadenosine","volume":"121","author":"Carson","year":"1978","journal-title":"Journal of Immunology"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1172\/JCI111710","article-title":"Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes","volume":"75","author":"Seto","year":"1985","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB8","series-title":"Physicians\u2019 Desk Reference","article-title":"Leustatin\u00ae (cladribine)","author":"Walsh","year":"2002"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB9","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1995.13.3.570","article-title":"2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia","volume":"13","author":"Saven","year":"1995","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB10","first-page":"679","article-title":"High complete remission rate from 2-chloro-2\u2032-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease in blood lymphocyte count","volume":"11","author":"Juliusson","year":"1993","journal-title":"Journal of Surgical Oncology"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428199109068099","article-title":"2-Chlorodeoxyadenosine (2-CdA): a potent chemotherapeutic and immunosuppressive nucleotide","volume":"5","author":"Beutler","year":"1991","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB12","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1056\/NEJM199210083271504","article-title":"Complete response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine","volume":"327","author":"Juliusson","year":"1992","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1200\/JCO.1992.10.3.371","article-title":"2-Chlorodeoxyadenosine treatment of low-grade lymphomas","volume":"10","author":"Kay","year":"1992","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/bjc.1993.24","article-title":"2-Chlorodeoxyadenosine: Evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies","volume":"67","author":"Hickish","year":"1993","journal-title":"British Journal of Cancer"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7326\/0003-4819-118-3-199302010-00007","article-title":"Treatment of Waldenstr\u00f6m macroglobulinemia with 2-chlorodeoxyadenosine","volume":"118","author":"Dimopoulos","year":"1993","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB16","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood.V80.3.587.587","article-title":"2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma","volume":"80","author":"Saven","year":"1992","journal-title":"Blood"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB17","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1200\/JCO.1992.10.3.364","article-title":"2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia","volume":"10","author":"Santana","year":"1992","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB18","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1073\/pnas.81.7.2232","article-title":"Antileukemia and immunosuppressive activity of 2-chloro-2\u2032-deoxyadenosine","volume":"81","author":"Carson","year":"1981","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB19","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1002\/1097-0142(19940615)73:12<2953::AID-CNCR2820731212>3.0.CO;2-V","article-title":"Complete hematologic remissions in chronic-phase Philadelphia chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine","volume":"73","author":"Saven","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB20","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.1993.11.4.671","article-title":"2-Chlorodeoxyadenosine dose escalation in non-hematologic malignancies","volume":"11","author":"Saven","year":"1993","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB21","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM199309023291013","article-title":"2-Chlorodeoxyadenosine to treat refractory histiocytosis X (letter)","volume":"329","author":"Saven","year":"1993","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(94)91046-4","article-title":"Cladribine in treatment of chronic progressive multiple sclerosis","volume":"344","author":"Sipe","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB23","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1073\/pnas.93.4.1716","article-title":"The treatment of chronic progressive multiple sclerosis with cladribine","volume":"93","author":"Beutler","year":"1996","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB24","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1002\/art.1780381112","article-title":"Oral 2-chlorodeoxyadenosine in psoriatic arthritis. A preliminary report","volume":"38","author":"Eibschutz","year":"1995","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/1529-0131(199802)41:2<335::AID-ART18>3.0.CO;2-O","article-title":"A pilot study of 2-chloro-2\u2032-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis","volume":"41","author":"Davis","year":"1998","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/10428199109103394","article-title":"2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia","volume":"5","author":"Saven","year":"1991","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB27","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood.V89.5.1838","article-title":"Weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a new treatment schedule effective and safer in preventing infectious complications (letter)","volume":"89","author":"Lauria","year":"1998","journal-title":"Blood"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB28","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1200\/JCO.1992.10.10.1514","article-title":"On the bioavailability of oral and subcutaneous 2-chloro-2\u2032-deoxyadenosine in humans: alternative routes of administration","volume":"10","author":"Liliemark","year":"1992","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB29","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1200\/JCO.1996.14.3.978","article-title":"Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy","volume":"14","author":"Saven","year":"1996","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB30","first-page":"597A","article-title":"Remission induction in hairy cell leukemia by treatment with 2-chlorodeoxyadenosine: role of DNA strand breaks and NAD depletion","volume":"35","author":"Carrera","year":"1987","journal-title":"Clinical Research"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB31","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJM199004193221605","article-title":"Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine","volume":"322","author":"Piro","year":"1990","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB32","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1182\/blood.V92.6.1918","article-title":"Long-term follow-up of patients with hairy cell leukemia after cladribine treatment","volume":"92","author":"Saven","year":"1998","journal-title":"Blood"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB33","article-title":"Extended follow-up of patients with hairy-cell leukemia following treatment with cladribine","author":"Goodman","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB34","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1182\/blood.V82.6.1798.1798","article-title":"Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia","volume":"82","author":"Hakimian","year":"1993","journal-title":"Blood"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB35","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood.V84.12.4310.bloodjournal84124310","article-title":"Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia","volume":"84","author":"Ellison","year":"1994","journal-title":"Blood"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB36","first-page":"1153","article-title":"A single course of 2-chlorodeoxyadenosine does not eradicate leukemic cells in hairy cell patients in complete remission","volume":"8","author":"Filleul","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB37","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.1997.15.3.1138","article-title":"Treatment of hairy cell leukemia with cladribine: Response toxicity and long-term follow-up","volume":"15","author":"Hoffman","year":"1997","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB38","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood.V88.6.1954.bloodjournal8861954","article-title":"Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience","volume":"88","author":"Tallman","year":"1996","journal-title":"Blood"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB39","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.1998.16.9.3007","article-title":"Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C Protocol Mechanism of the National Cancer Institute: a report of 979 patients","volume":"16","author":"Cheson","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB40","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood.V93.8.2471","article-title":"Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia","volume":"93","author":"Saven","year":"1999","journal-title":"Blood"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB41","first-page":"371","article-title":"Neutropenic fever following cladribine therapy for symptomatic hairy cell leukemia: predictive factors and effects of granulocyte\u2013macrophage colony-stimulating factor","volume":"6","author":"Juliusson","year":"1995","journal-title":"Advances in Oncology"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB42","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood.V83.10.2906.2906","article-title":"2-Chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia","volume":"83","author":"Seymour","year":"1994","journal-title":"Blood"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB43","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0162-3109(93)90035-O","article-title":"Cladribine (2-chlorodeoxyadenosine): an inhibitor of human B and T cell activation in vitro","volume":"26","author":"Gorski","year":"1993","journal-title":"Immunopharmacology"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB44","first-page":"5570","article-title":"On the pharmacokinetics of 2-chloro-2\u2032-deoxyadenosine in humans","volume":"51","author":"Liliemark","year":"1991","journal-title":"Cancer Research"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB45","unstructured":"Ries LAG, Miller BA, Hankey BF et al. SEER Cancer Statistics Review, 1973\u20131991: Tables and Graphs, National Cancer Institute. Bethesda, MD: National Institutes of Health Publication Number 94-2789, 1994."},{"key":"10.1016\/S1521-6926(02)00089-0_BIB46","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/0002-9343(80)90259-4","article-title":"Infections of hairy cell leukaemia. Clinical evidence of a pronounced defect in cell-mediated immunity","volume":"68","author":"Mckowiak","year":"1980","journal-title":"American Journal of Medicine"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB47","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood.V61.6.1132.1132","article-title":"Severe deficiency of natural killer activity in the peripheral blood of patients with hairy cell leukemia","volume":"61","author":"Ruco","year":"1983","journal-title":"Blood"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB48","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1200\/JCO.1999.17.8.2454","article-title":"Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias","volume":"17","author":"Cheson","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB49","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1182\/blood.V92.4.1160","article-title":"Second malignancies in patients with hairy cell leukemia in British Columbia: a 20-year experience","volume":"92","author":"Au","year":"1998","journal-title":"Blood"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB50","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.1997.15.5.1803","article-title":"Second cancer risk in hairy cell leukemia: analysis of 350 patients","volume":"15","author":"Kurzrock","year":"1997","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB51","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0268-960X(89)90013-1","article-title":"Purine metabolism as a target for leukemia chemotherapy","volume":"3","author":"Riscoe","year":"1989","journal-title":"Blood Reviews"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB52","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1200\/JCO.1984.2.12.1336","article-title":"Hairy cell leukemia: induction of complete remission with pentostatin (2\u2032-deoxycoformycin)","volume":"2","author":"Spiers","year":"1984","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB53","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2141.1986.tb07530.x","article-title":"The treatment of hairy cell leukaemia with 2\u2032-deoxycoformycin","volume":"63","author":"Johnston","year":"1986","journal-title":"British Journal of Haematology"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB54","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1200\/JCO.1991.9.2.243","article-title":"Pentostatin induces durable remissions in hairy cell leukemia","volume":"9","author":"Cassileth","year":"1991","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB55","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/jnci\/82.17.1416","article-title":"Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer","volume":"82","author":"Ho","year":"1990","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB56","first-page":"38","article-title":"Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia","volume":"73","author":"Urba","year":"1989","journal-title":"Blood"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB57","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1200\/JCO.1990.8.5.848","article-title":"Immunosuppressive effects of pentostatin","volume":"8","author":"Kraut","year":"1990","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB58","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0140-6736(84)91491-0","article-title":"Complete remission in hairy cell leukaemia achieved with pentostatin","volume":"1","author":"Spiers","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB59","doi-asserted-by":"crossref","first-page":"278","DOI":"10.7326\/0003-4819-119-4-199308150-00005","article-title":"Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2\u2032-deoxycoformycin","volume":"119","author":"Saven","year":"1993","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB60","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1995.13.4.974","article-title":"Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an Intergroup Study","volume":"13","author":"Grever","year":"1995","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB61","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1182\/blood.V83.12.3672.3672","article-title":"Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine","volume":"83","author":"Juliusson","year":"1994","journal-title":"Blood"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB62","first-page":"929","article-title":"Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine","volume":"9","author":"Seymour","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB63","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1182\/blood.V100.2.647","article-title":"Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion","volume":"100","author":"Baker","year":"2002","journal-title":"Blood"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB64","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0145-2126(00)00090-4","article-title":"Therapeutic advances in the treatment of hairy cell leukemia","volume":"25","author":"Andrey","year":"2001","journal-title":"Leukemia Research"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB65","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1073\/pnas.80.14.4522","article-title":"Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia","volume":"80","author":"Korsmeyer","year":"1983","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB66","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/ajcp\/80.4.421","article-title":"Hairy cell leukemia: a B-cell neoplasm with a unique antigenic phenotype","volume":"80","author":"Hsu","year":"1983","journal-title":"American Journal of Clinical Pathology"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB67","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/ajcp\/83.3.289","article-title":"The differential diagnosis of hairy cell leukemia with a panel of monoclonal antibodies","volume":"83","author":"Falini","year":"1985","journal-title":"American Journal of Clinical Pathology"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB68","first-page":"705a","article-title":"Pilot study of rituximab in refractory or relapsed hairy cell leukemia (HCL)","volume":"94","author":"Thomas","year":"2000","journal-title":"Blood"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB69","first-page":"964a","article-title":"Phase II study of rituximab in the treatment of cladribine-failed patients with hairy-cell leukemia","volume":"98","author":"Nieva","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB70","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/1097-0142(19910301)67:5<1291::AID-CNCR2820670503>3.0.CO;2-Y","article-title":"Fludarabine therapy in hairy cell leukemia","volume":"67","author":"Kantarjian","year":"1991","journal-title":"Cancer"},{"issue":"supplement 8","key":"10.1016\/S1521-6926(02)00089-0_BIB71","first-page":"66","article-title":"Fludarabine phosphate therapy in other lymphoid malignancies","volume":"17","author":"Kantarjian","year":"1990","journal-title":"Seminars in Oncology"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB72","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajh.2830370116","article-title":"Fludarabine phosphate in refractory hairy cell leukemia","volume":"37","author":"Kraut","year":"1991","journal-title":"American Journal of Hematology"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB73","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJM200107263450402","article-title":"Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia","volume":"345","author":"Kreitman","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB74","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1182\/blood.V79.4.882.bloodjournal794882","article-title":"Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA)","volume":"79","author":"Estey","year":"1992","journal-title":"Blood"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB75","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1365-2141.1999.01546.x","article-title":"Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine","volume":"106","author":"Dearden","year":"1999","journal-title":"British Journal of Haematology"},{"key":"10.1016\/S1521-6926(02)00089-0_BIB76","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood.V79.4.888.bloodjournal794888","article-title":"Rapid recovery from cytopenia in hairy cell leukaemia after treatment with 2-chloro-2\u2032-deoxyadenosine (CdA): relation to opportunistic infections","volume":"79","author":"Juliusson","year":"1992","journal-title":"Blood"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692602000890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692602000890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T02:55:25Z","timestamp":1682477725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692602000890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["S1521692602000890"],"URL":"https:\/\/doi.org\/10.1016\/s1521-6926(02)00089-0","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2003,3]]}}}